Synoptical view

    Truffle investment
    € 15M
    Stock
    Pharnext is listed on EURONEXT GROWTH PARIS since 2016
pharmnext.jpg

Management team

dr_david_horn_solomon.jpg

Dr. David Horn Solomon

CEO

adrian_hepner.jpg

Adrian Hepner, MD, PhD

CMO

Board of Directors

michel_de_rosen.jpg

Michel de Rosen

President

In summary

Pharnext has two flagship products in clinical development, one for the treatment of Charcot-Marie-Tooth disease type 1A, the other for the treatment of Alzeimer's disease. Pharnext has developed a new paradigm for drug discovery based on large genomic data and artificial intelligence: PLEOTHERAPY. The company identifies and develops synergistic drug combinations

News

Press Release
logo_pharnext_gb.jpg

Pharnext Announces Identification of a Large Set of Frequently Prescribed Drugs to be Repurposed for Fighting COVID-19

image_1.jpg

Next start-up

Piezomedic